Brian Wilson has revealed the track listing for his trade name new album �??That Lucky Old Sun�??, place to be released September 2.
The criminal record will come out on CD, DVD and digitally, as well as on a limited edition vinyl which will came proscribed on August 19.
�??That Lucky Old Sun�?? sees the former Beach Boy render to Capitol records, the label that was originally home to his band back in the 1960s.
The Beach Boys �??Surfin�?? Safari/409�?? was released via the imprint in 1962 and Wilson says he is thrilled to be back at the label.
"I'm thrilled to be back home with Capitol, and I'm looking forward to sharing �??That Lucky Old Sun�?? with everyone. This music is really special to me."
Inspired by the 1949 strain �??That Lucky Old Sun�??, Wilson debuted the album in London in September 2007 in a series of six sold-out shows at the Royal Albert Hall.
Produced by Wilson himself, the album was recorded at Capitol Studios in Hollywood, where he first recorded in 1962.
The track listing is:
�??That Lucky Old Sun�??
�??Morning Beat�??
�??Narrative: Room With A View�??
�??Good Kind Of Love�??
�??Forever She'll Be My Surfer Girl�??
�??Narrative: Venice Beach�??
�??Live Let Live/That Lucky Old Sun�?? (reprise)
�??Mexican Girl�??
�??Narrative: Cinco de Mayo�??
�??California Role/That Lucky Old Sun�?? (repeat)
�?? Narrative: Between Pictures�??
�??Oxygen To The Brain�??
�??Can't Wait Too Long�??
�??Midnight's Another Day�??
�??That Lucky Old Sun�?? (reprise)
�??Going Home�??
�??Southern California�??
--By our New York staff.
Find forbidden more around NME.
More info
Sunday, 7 September 2008
Thursday, 28 August 2008
BRIDION(R) (sugammadex) Injection - First And Only Selective Relaxant Binding Agent - Approved In European Union
�Schering-Plough Corporation (NYSE: SGP) announced that the European Commission (EC) has approved BRIDION(R) (sugammadex) injection, the first and only selective relaxant binding agent (SRBA) and the first major pharmaceutical further in the field of anesthesia in two decades. BRIDION is indicated for routine reversal of the commonly secondhand muscle relaxants rocuronium or vecuronium and for immediate reversal of rocuronium in adults, and for routine reversal following rocuronium in children and adolescents (2-17 years of age). Rocuronium and vecuronium are minded as part of general anesthesia to relax a patient's muscles during surgical procedure, and are marketed in Europe under the trade names ESMERON(R) and NORCURON(R), respectively.
BRIDION works in an completely novel way by encapsulating the heftiness relaxant atom and translation it inactive. It was specifically designed to reverse within minutes both soften and deep muscle relaxation induced by rocuronium or vecuronium during general anaesthesia. As a result, BRIDION can give anesthesiologists greater control in managing the depth of muscle relaxation through to the final stage of a surgical subroutine. This may help better surgical conditions in the millions of procedures where these agents are used.
"This approval of BRIDION represents the first advance in two decades for anesthesiologists and their patients, and has the potential to transform the practice of anesthesia," said Thomas P. Koestler, Ph.D., executive vice president and president of Schering-Plough Research Institute. "This is the first major approval of a product from our combination with Organon BioSciences and is a significant achievement for Schering-Plough. This further validates the value of our combination, which closed in November 2007, and is already making a positivistic contribution to our business."
BRIDION has a rapid onset and, in addition to routine reversal, can be used in critical situations when prompt reversal of rocuronium is needed. In BRIDION clinical studies, the median metre to reversal of rocuronium was about three minutes.
A muscle relaxant plays respective critical roles in general anesthesia. Anesthesiologists use muscle relaxation to improve operative conditions and to facilitate intubation and mechanical respiration. Reversal agents reverse the effects of muscle relaxants, enabling patients to find normal muscular tissue function earlier and suspire on their own. Current reversal agents are slow and ar associated with certain undesirable side personal effects, including cardiac rhythm disturbances and gI and pulmonic side effects.
"The ability to rapidly reverse both temper and deep levels of muscle relaxation during cosmopolitan anesthesia was not possible before BRIDION," said Rajinder Mirakhur, M.D., professor of anesthetics at The Queen's University of Belfast, Northern Ireland, and a principal investigator in the BRIDION clinical trials program. "BRIDION can provide us with greater flexibility to have and maintain the stratum of musculus relaxation with rocuronium or vecuronium necessary throughout surgery and contrary that relaxation quickly when needed."
BRIDION (sugammadex) Clinical Trials
The EC approval of BRIDION is based on an extensive clinical trial database of close to 1,800 patients and volunteers, including data from the SIGNAL, AURORA and SPECTRUM clinical trials. The SIGNAL trial involved adult patients undergoing surgery. Rocuronium was administered at a standard loony toons to allow intubation, followed by upkeep doses as required. When 1-2 post-tetanic counts (PTC) were ascertained following neuromuscular stimulation (deep block), patients were administered either sugammadex or neostigmine plus glycopyrrolate, a current reversal regimen. In the SIGNAL run, the median time to reversal of muscle relaxation behavior to a train-of-four (TOF) ratio of 0.9 occurred in 2.7 minutes in the sugammadex group compared to 49.0 proceedings in the 170% 2007 under the brand
BRIDION works in an completely novel way by encapsulating the heftiness relaxant atom and translation it inactive. It was specifically designed to reverse within minutes both soften and deep muscle relaxation induced by rocuronium or vecuronium during general anaesthesia. As a result, BRIDION can give anesthesiologists greater control in managing the depth of muscle relaxation through to the final stage of a surgical subroutine. This may help better surgical conditions in the millions of procedures where these agents are used.
"This approval of BRIDION represents the first advance in two decades for anesthesiologists and their patients, and has the potential to transform the practice of anesthesia," said Thomas P. Koestler, Ph.D., executive vice president and president of Schering-Plough Research Institute. "This is the first major approval of a product from our combination with Organon BioSciences and is a significant achievement for Schering-Plough. This further validates the value of our combination, which closed in November 2007, and is already making a positivistic contribution to our business."
BRIDION has a rapid onset and, in addition to routine reversal, can be used in critical situations when prompt reversal of rocuronium is needed. In BRIDION clinical studies, the median metre to reversal of rocuronium was about three minutes.
A muscle relaxant plays respective critical roles in general anesthesia. Anesthesiologists use muscle relaxation to improve operative conditions and to facilitate intubation and mechanical respiration. Reversal agents reverse the effects of muscle relaxants, enabling patients to find normal muscular tissue function earlier and suspire on their own. Current reversal agents are slow and ar associated with certain undesirable side personal effects, including cardiac rhythm disturbances and gI and pulmonic side effects.
"The ability to rapidly reverse both temper and deep levels of muscle relaxation during cosmopolitan anesthesia was not possible before BRIDION," said Rajinder Mirakhur, M.D., professor of anesthetics at The Queen's University of Belfast, Northern Ireland, and a principal investigator in the BRIDION clinical trials program. "BRIDION can provide us with greater flexibility to have and maintain the stratum of musculus relaxation with rocuronium or vecuronium necessary throughout surgery and contrary that relaxation quickly when needed."
BRIDION (sugammadex) Clinical Trials
The EC approval of BRIDION is based on an extensive clinical trial database of close to 1,800 patients and volunteers, including data from the SIGNAL, AURORA and SPECTRUM clinical trials. The SIGNAL trial involved adult patients undergoing surgery. Rocuronium was administered at a standard loony toons to allow intubation, followed by upkeep doses as required. When 1-2 post-tetanic counts (PTC) were ascertained following neuromuscular stimulation (deep block), patients were administered either sugammadex or neostigmine plus glycopyrrolate, a current reversal regimen. In the SIGNAL run, the median time to reversal of muscle relaxation behavior to a train-of-four (TOF) ratio of 0.9 occurred in 2.7 minutes in the sugammadex group compared to 49.0 proceedings in the 170% 2007 under the brand
Monday, 18 August 2008
Mp3 music: Slightly Stoopid
 Artist: Slightly Stoopid: mp3 download Genre(s): Rock Other Slightly Stoopid's discography:  Chronchitis Year: 2007 Tracks: 17  Closer to the Sun Year: 2005 Tracks: 20  Live and Direct: Acoustic Roots Year: 2004 Tracks: 15  Everything You Need Year: 2003 Tracks: 14  The Longest Barrel Ride Year: 1998 Tracks: 20 Slightly Stoopid's Miles Doughty and Kyle McDonald were sign-language to Sublime brainiac Brad Nowell's Skunk imprint piece still in high school, and did iI albums for the pronounce, More or less Stoopid in 1996 and Longest Barrel Ride two age later. While the reasoned back then was SoCal skatepunk influenced by thresh elements and rich amounts of mourning band, Doughty and McDonald's playing and singing had mature well by 2001 and Live & Direct: Acoustic Roots. The duet was later rounded by drummer Rob Moran and percussionist/vocalist Oguer Ocon. By 2003 and Everything You Need, they were rocking a California-centric healthy of crackers sampledelic drink down, hip-hop influence, cheery ganja affirmations, and the episodic return to strident skatepunk. In 2005, Slightly Stoopid released their nearly completed album to date, Closer to the Sun. The record miscellaneous dub and reggae influences with light hip-hop and an well-off groove -- on tracks like "Ain't Got a Lot of Money," Doughty and McDonald suggested Jack Johnson fronting Fun Lovin' Criminals. Their eclecticist integrate of sounds institute the circle on tours over the eld with a assortment of bands including the Marley Brothers, blink-182, G. Love & Special Sauce, Pennywise, and N.E.R.D. Considering Slightly Stoopid's longtime and adamantly D.I.Y. work ethical code, Finisher to the Sun imposingly debuted in the Billboard Top two hundred and sold intimately 25,000 copies in its number unitary deuce months of outlet. The EP Slightly Not Stoned Enough to Eat Breakfast Yet Stoopid appeared future, which contained Sun outtakes and early classic studio recordings. Playing closely 200 shows a year for their diverse fan infrastructure dear termed Ese Locos or Stoopidheads, the mathematical mathematical group released a live album (Wintertime Tour '05-'06) and DVD (Unrecorded in San Diego) in June 2006. The releases reflected the band's propensity to jam for almost deuce hours at their gigs, focusing on improvisation and crowd together interaction. |
TMC278 Demonstrates Long-Term Efficacy And Tolerability In Treatment-Naïve Adults With HIV
Friday, 8 August 2008
Tuesday, 1 July 2008
Charles Lloyd - Geri Allen duo
Artist: Charles Lloyd - Geri Allen duo
Genre(s):
Jazz
Discography:
Live in Cully Jazz Festival 2004
Year: 2004
Tracks: 5
Telepherique
Friday, 27 June 2008
Toronto slates North American premieres
'Gomorrah,' 'The Class' added to festival lineup
TORONTO -- The Toronto International Film Festival said Thursday that it will give South Korean filmmaker Kim Jee-woon's "The Good, the Bad and the Weird" the red carpet treatment in September as it announced about two dozen North American premieres for films that bowed at Cannes, Berlin or elsewhere internationally.
Toronto also booked Italian director Matteo Garrone's "Gomorrah," which earned the Grand Prix in Cannes, Canadian filmmaker Atom Egoyan's "Adoration" and two French films -- Arnaud Desplechin's "Un conte de Noel" and Laurent Cantet's "The Class" -- for its Special Presentations sidebar.
The festival's Masters sidebar programmed "24 City," from Chinese director Jia Zhang-ke, Jerzy Skolimowski's "Four Nights With Anna," a Poland-France co-production, the Cannes best screenplay winner "Lorna's Silence," from Belgium's Dardenne brothers, British director Terence Davies' "Of Time and the City" and "Three Monkeys," which earned director Nuri Bilge Ceylan the best director trophy at Cannes.
Toronto also booked the documentary "Blind Loves," from Slovakian director Juraj Lehotsky, for its Real to Reel section, while Lisandro Alonso's "Liverpool" and "Service," by Brillante Mendoza, get Visions slots.
The Contemporary World Cinema sidebar booked three Latin American titles -- Federico Veiroj's "Acne," Brazil's "Linha de Passe," from Walter Salles and Daniela Thomas, and Pablo Trapero's "Lion's Den" -- along with Bent Hamer's "O'Horten," Amos Kollek's "Restless" and Gotz Spielmann's "Revanche."
The Discovery program will feature Steve McQueen's "Hunger," which earned the Camera d'Or in Cannes, U.S. filmmaker Barry Jenkins' "Medicine for Melancholy," Argentinean director Gabriel Medina's "The Paranoids," Pablo Aguero's "Salamandra," Matthew Newton's "Three Blind Mice," Pablo Larrain's "Tony Manero" and Sergey Dvortsevoy's "Tulpan."
Rounding out the Toronto lineup is Ari Folman's "Waltz With Bashir" in the Vanguard section.
The 33rd Toronto International Film Festival is set for Sept. 4-13.
See Also
Sarah Jessica Parker lines up 'Ivy'
In talks to star in her first project after 'Sex and the City'
Sarah Jessica Parker could soon have her first project after "Sex."
The actress is in talks with Warner Bros. to star in "The Ivy Chronicles," a story of class and the single woman in contemporary New York. It centers on Ivy Ames, an Upper East Side woman who, after losing her high-powered job and getting divorced, starts over again in a less ritzy downtown apartment. After pulling her children from private school, Ames starts a business to help upper-middle-class women get their children into elite kindergartens.
The project, based on Karen Quinn's eponymous novel, is described as following in the vein of "The Devil Wears Prada" and "The Nanny Diaries" as well as Gigi Levangie Grazer's "The Starter Wife," which became a successful limited series on USA. Jerry Weintraub is set to produce.
Warners is keen to cast Parker in another project after "Sex and the City" became one of the blowout hits of the summer, earning more than $300 million worldwide. Several projects were presented to the actress, who sparked to the single-mother tale.
About eight months before "Sex" became a summer smash, Parker had signed on to a romantic comedy titled "The Late Bloomer's Revolution," which HBO Films was to have produced for Picturehouse; with the dissolution of the unit, that project's status is uncertain.
Parker has had mixed big-screen results outside of "Sex." Recent academia dramedy "Smart People" earned only $10 million at the boxoffice, though "Failure to Launch," a film in which Parker had a leading role opposite Matthew McConaughey, wound up earning nearly $90 million domestically for Paramount in 2006.
See Also
Subscribe to:
Posts (Atom)